ASCO today presented Representatives Ben Ray Luján (NM-3) and Gus Bilirakis (FL-12) with its annual Congressional Leadership Award in recognition of the lawmakers' exceptional, bipartisan commitment to supporting cancer research and treatment. The ASCO award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their cancer care teams.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
The American Society of Clinical Oncology (ASCO) presented its 2018 Advocate of the Year Award to Alexandra Thomas, MD, for her exceptional contributions and commitment to the society’s policy and advocacy efforts. As a 2017-2018 participant in ASCO’s Leadership Development Program (LDP), Dr. Thomas went above and beyond to improve research and access to treatment for people living with cancer.
Roughly one in five young adults uses e-cigarettes daily or recreationally, and nearly one in four believes the products are harmless and not addictive, according to findings from ASCO’s third annual National Cancer Opinion Survey. This comes after the Centers for Disease Control and Prevention (CDC) issued the results from its National Youth Tobacco Survey earlier this month, reporting that e-cigarette use among pre-teens and teens is on the rise. It is also despite warnings from the U.S. Surgeon General that e-cigarettes (also known as vapes) contain addictive and harmful or potentially harmful ingredients, including nicotine; lead and other heavy metals; and flavorants such as diacetyl, a chemical linked to serious lung disease. Amid public debate over banning flavored e-cigarettes, the ASCO survey also found that nearly three in 10 young adults think flavored e-cigarettes are less damaging to a person’s health than non-flavored ones. In addition, nearly seven in 10 Americans support raising the legal age to purchase e-cigarettes from 18 to 21.
An overview of ASCO's initiatives in the area of survivorship care.
ASCO Board Member Blase N. Polite, MD, MPA, FASCO, provided a keynote address to the European Cancer Summit on September 14 that was written up in The Parliament Magazine.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to a proposed rule that would loosen state reporting requirements and potentially threaten access to cancer care for Medicaid beneficiaries. ASCO believes all patients should have access to high-quality, high-value cancer care and is concerned that CMS’ proposal would jeopardize that access.
During ASCO's upcoming Advocacy Summit, oncology care providers will urge lawmakers to improve clinical trial access, protect patients from unnecessary care delays, ensure acess to potentially lifesaving medications, and foster continued success of the MACRA program. ASCO members are invited to participate virtually through the ACT Network.
On September 17, 2019, the Food and Drug Administration granted accelerated approval to the combination of pembrolizumab (KEYTRUDA®, Merck) plus lenvatinib (LENVIMA, Eisai) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.
The American Medical Association (AMA) and Manatt Health have released, “National Roadmap on State-Level Efforts to End the Opioid Epidemic,” an analysis identifying effective state policies against the national opioid epidemic.
In a new interview on the ASCO in Action podcast episode, ASCO President Dr. Howard A. “Skip” Burris discusses why he became an oncologist, the importance of mentors in his professional career, the most significant changes he’s witnessed in cancer care during the past three decades, and his vision and hope for the coming year as he serves in this top ASCO volunteer position.
On September 17, 2019, the Food and Drug Administration approved apalutamide (ERLEADA®, Janssen Biotech, Inc) for patients with metastatic castration-sensitive prostate cancer (mCSPC). Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.
ASCO joined 370 health care groups in urging members of the U.S. House of Representatives to support the Improving Seniors’ Timely Access to Care Act (H.R. 3107). The bipartisan bill would help protect patients from unnecessary care delays by streamlining and standardizing prior authorization under Medicare Advantage (MA) and providing program oversight and transparency for MA beneficiaries.
A new study in the Journal of Oncology Practice (JOP) comparing the use of subacute rehabilitation (SAR) instead of hospice referral since the availably of immunotherapy finds a growing number of people with cancer are being discharged to SAR, but approximately two-thirds do not receive further cancer therapy at any point. This research provides important insights for goals of care.